InvestorsHub Logo
Followers 2543
Posts 250734
Boards Moderated 34
Alias Born 05/06/2014

Re: None

Saturday, 07/04/2015 6:27:10 PM

Saturday, July 04, 2015 6:27:10 PM

Post# of 32013
$MNKD MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin

One more noteworthy set of numbers: Afrezza is having no impact at all on market share of competing injectable, mealtime insulins.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MNKD News